Infective endocarditis resident survival guide
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farman Khan, MD, MRCP [2]; Mohamed Moubarak, M.D. [3]
Definition
Infection of the endothelium of the heart including but not limited to the valves. It can be either acute or subacute. Acute bacterial endocarditis is defined as Infection of normal heart valves with a virulent organism like S. aureus, Group A or other beta-hemolytic streptococci, Streptococcus pneumoniae. Subacute bacterial endocarditis is an indolent infection of abnormal valves with less virulent organism like Streptococcus viridans.
Criteria | Definite Infective Endocarditis According to Modified Duke Criteria |
---|---|
Pathological Criteria |
|
Clinical Criteria |
|
Possible IE |
|
Rejected |
|
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Endocarditis can be a life-threatening condition if it is left untreated, and it must be treated as such irrespective of the causes.
Common Causes
Management
Diagnostic Criteria
Shown below is an algorithm depicting the diagnostic criteria of infective endocarditis based on the 2005 American Heart Association (AHA) technical review and medical position statement regarding guidelines on infective endocarditis.[1]
Duke Criteria | |||||||||||||||||||||||||||||||||||||||||||||||||||
The Duke Clinical Criteria for Infective Endocarditis requires either:
❑ Two major criteria, or ❑ One major and three minor criteria, or ❑ Five minor criteria | |||||||||||||||||||||||||||||||||||||||||||||||||||
Major Criteria | Minor criteria | ||||||||||||||||||||||||||||||||||||||||||||||||||
Positive Blood Culture for Infective Endocarditis
Echocardiographic evidence of endocardial involvement
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnostic approach
Shown below is an algorithm summarizing the approach to infective endocarditis.
Characterize the symptoms:
❑ Onset of the symptoms
❑ Fever | |||||||||||||||||||||||||||||
Identify existing risk factors: ❑ History of rheumatic heart disease
| |||||||||||||||||||||||||||||
Examine the patient: Vital signs
Skin ❑ Petechiae Eyes ❑ Conjunctival hemorrhage Heart Lungs ❑ Rales as a sign of heart failure Abdomen ❑ Reduced bowel sounds (sign of mesenteric embolization or ileus)
Extremities ❑ Janeway lesions (painless hemorrhagic cutaneous lesions on the palms and soles) Neurologic ❑ Full neurological exam
| |||||||||||||||||||||||||||||
Does the patient have any of the following: ❑ Unexplained fever for more than 48 hours and high risk for infective endocarditis
❑ Newly diagnosed valve regurgitation | |||||||||||||||||||||||||||||
Order laboratory tests:[2] ❑ Blood culture (at least two sets)
❑ Erythrocyte sedimentation rate
❑ BUN ❑ EKG | |||||||||||||||||||||||||||||
❑ Order a TTE
| |||||||||||||||||||||||||||||
Reevaluate the patient with TTE and/or TEE
❑ Change in clinical signs and symptoms
❑ High risk of complications
| |||||||||||||||||||||||||||||
Evaluate the Modified Duke Criteria for infective endocarditis: ❑ Two major criteria, OR | |||||||||||||||||||||||||||||
❑ Begin antibiotic treatment (look below for details)
❑ Schedule early surgery during hospitalization before completion of the antibiotics course in case of
❑ Remove the pacemaker of the defibrillator system in case of
| |||||||||||||||||||||||||||||
❑ Consult an infectious disease specialist ❑ Consult a cardiologist ❑ Consult a cardiac surgeon | |||||||||||||||||||||||||||||
Therapeutic Approach
Shown below an algorithm depicting the general therapeutic approaches of infective endocarditis based on the 2005 American Heart Association (AHA) technical review and medical position statement regarding guidelines on infective endocarditis.[3]
❑ Evaluate the patient | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Acute presentation or hemodynamically unstable | ❑ Subacute presentation and hemodynamically stable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Stabilize the patient | ❑ Wait for blood culture results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Don`t wait for blood culture results and start empirical antibiotic therapy | Start antibiotic therapy according to the detected pathogen | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Streptococci antibiotic regimen | Enterococci antibiotic regimen | Staphylococci antibiotic regimen | HACEK Organisms antibiotic regimen | Culture negative antibiotic regimen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prophylactic Approach
Shown below an algorithm depicting the general prophylactic approaches of infective endocarditis based on 2014 AHA/ACC Guideline for the management of patients with valvular heart disease.[4]
Identify high risk patients: (Class IIa, Level of evidence B)
❑ Prosthetic valves patients
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Identify high risk procedures: ❑ Procedures on infected skin or musculoskeletal tissue ❑ Respiratory tract procedures ❑ Gastrointestinal and genitourinary procedures ❑ Patients undergoing cardiac surgery ❑ Dental procedures | |||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Decide if the patient needs prophylaxis | |||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Choose a prophylaxis regimen | |||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Infective endocarditis prophylaxis regimens | ❑ Prophylaxis regimens if the patient is penicillin or pmpicillin allergic | ❑ Prophylaxis regimens if the patient is penicillin or ampicillin allergic and cannot take oral medications | |||||||||||||||||||||||||||||||||||||||||||||||||||
Do's
- Elicit a full medical history to help detecting the minor Duke criteria for the diagnosis.
- Initiate antibiotic therapy after withdrawing blood for culture (Class I, level of evidence B).
- Do a TEE intraoperatively among patients scheduled for valve surgery for infective endocarditis (Class I, level of evidence B).
- Consider ordering a cardiac CT scan when echocardiography does not provide clear details about the cardiac anatomy in the context of suspected paravalvular infections (Class IIa, level of evidence B).
Dont's
- Don't administer prophylaxis for infective endocarditis in patients with valvular heart disease who are at risk infective endocarditis for procedures such as TEE, cystoscopy, esophagogastroduodenoscopy or colonoscopy without any evidence of active infection (Class III; level of evidence B).
References
- ↑ Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.
- ↑ Bonow RO, Carabello BA, Chatterjee K; et al. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter
|month=
ignored (help) - ↑ Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter
|month=
ignored (help) - ↑ "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Retrieved 4 March 2014.